Muscle News and Research

RSS

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

Active video games may benefit kids with cerebral palsy

Like their healthy peers, children with disabilities may spend too much time in front of a video screen. For children with cerebral palsy (CP), this leads to an even greater risk of being overweight or developing health issues such as diabetes or musculoskeletal disorders.

7 May 2012

Seattle Children's Hospital performs 100th heart transplant on 5-month-old baby

On Saturday, April 28, a 5-month-old baby received the 100th heart transplant performed at Seattle Children's Hospital, a significant milestone for him as well as the hospital's Heart Center and Heart Transplant Program teams.

7 May 2012

Human stem cells effective in treating muscular dystrophy

Researchers from the University of Minnesota's Lillehei Heart Institute have effectively treated muscular dystrophy in mice using human stem cells derived from a new process that - for the first time - makes the production of human muscle cells from stem cells efficient and effective.

5 May 2012

New system measures strength of communication between muscle cells and motor neurons

In an effort to identify the underlying causes of neurological disorders that impair motor functions such as walking and breathing, UCLA researchers have developed a novel system to measure the communication between stem cell-derived motor neurons and muscle cells in a Petri dish.

5 May 2012

Growing role of body image drugs

In the current issue of Psychotherapy and Psychosomatics Kanayama et al. analyse the growing role of body image drugs.

4 May 2012

Researchers create new systematic assessment for malnutrition

A new systematic assessment of malnutrition, created by researchers at Penn State, will aid dietitians and other health care providers in diagnosis and treatment.

4 May 2012

First Edition: May 3, 2012

Today's headlines include a report exploring how the Medicare payment system could suffer unintended consequences if the Supreme Court overturns the health law.

3 May 2012

ADM hormone plays a significant role in tubal ectopic pregnancies

Tubal ectopic pregnancy (TEP) is currently the leading cause of pregnancy-related deaths during the first trimester and a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) shows that the hormone adrenomedullin (ADM) may help predict this condition.

3 May 2012

JS Genetics announces availability of XCAT-KS buccal swab test

JS Genetics announces the availability of XCAT-KS, its proprietary buccal swab test for the diagnosis of Klinefelter syndrome (KS) and other male sex chromosome aneuploidies.

3 May 2012

Bladder tests performed on women before SUI surgery may not be necessary

Invasive and costly tests commonly performed on women before surgery for stress urinary incontinence (SUI) may not be necessary, according to researchers at the University of California San Diego, School of Medicine and the Urinary Incontinence Treatment Network. The study, supported by the National Institutes of Health (NIH), will be released online May 2 by the New England Journal of Medicine.

3 May 2012

Hypothalamic neuropeptide changes cause obesity in low-birth-weight babies

It seems improbable that a baby born underweight would be prone to obesity, but it is well documented that these children tend to put on weight in youth if they're allowed free access to calories. Now, researchers believe they understand why this happens.

3 May 2012

Ligand first quarter total revenues increase to $5.6 million

Ligand Pharmaceuticals Incorporated today reported financial results for the first quarter ended March 31, 2012, and provided an operating forecast and program updates.

3 May 2012

PRDM16 transcription co-factor plays a critical role in development of embryonic palate

In the United States, a baby is born with a facial cleft every hour, of every day of the year! Such birth defects result from both gene mutations and environmental insults. PRDM16 is a transcription factor originally described as being aberrantly activated in specific types of leukemia's, and more recently as a master regulator of brown adipose tissue differentiation.

3 May 2012

Expression of tyrosine kinases may limit effectiveness of agents against sarcomas

To better understand the signaling pathways active in sarcomas, researchers at Moffitt Cancer Center used state-of-the-art mass spectrometry-based proteomics to characterize a family of protein enzymes that act as "on" or "off" switches important in the biology of cancer. The tyrosine kinases they identified, the researchers said, could act as "drivers" for the growth and survival of sarcomas.

2 May 2012

Rigel first quarter net loss increases to $23.2 million

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2012.

2 May 2012

Diagnosis of neonatal abstinence syndrome triples between 2000 and 2009

About one baby is born every hour addicted to opiate drugs in the United States, according to new research from University of Michigan physicians.

2 May 2012

Ultragenyx reports results from UX001 Phase 1 study on HIBM

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration

2 May 2012

Sanofi Pasteur announces new quadrivalent influenza vaccine Phase III pediatric data

Sanofi Pasteur, the vaccines division of Sanofi, announced today new Phase III data for its investigational quadrivalent influenza vaccine (QIV) in children 6 months through 8 years of age.

2 May 2012